QuidelOrtho (NASDAQ:QDEL – Get Free Report) and Innovative Eyewear (NASDAQ:LUCY – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation and risk.
Institutional and Insider Ownership
99.0% of QuidelOrtho shares are owned by institutional investors. Comparatively, 1.0% of Innovative Eyewear shares are owned by institutional investors. 1.1% of QuidelOrtho shares are owned by insiders. Comparatively, 1.7% of Innovative Eyewear shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares QuidelOrtho and Innovative Eyewear’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| QuidelOrtho | -39.20% | 4.88% | 1.63% |
| Innovative Eyewear | -272.42% | -83.37% | -76.02% |
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| QuidelOrtho | $2.73 billion | 0.36 | -$1.13 billion | ($15.41) | -0.94 |
| Innovative Eyewear | $2.66 million | 1.68 | -$7.59 million | ($1.69) | -0.41 |
Innovative Eyewear has lower revenue, but higher earnings than QuidelOrtho. QuidelOrtho is trading at a lower price-to-earnings ratio than Innovative Eyewear, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of recent ratings and price targets for QuidelOrtho and Innovative Eyewear, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| QuidelOrtho | 2 | 4 | 0 | 0 | 1.67 |
| Innovative Eyewear | 1 | 1 | 0 | 0 | 1.50 |
QuidelOrtho presently has a consensus target price of $13.62, suggesting a potential downside of 5.96%. Given QuidelOrtho’s stronger consensus rating and higher possible upside, equities research analysts plainly believe QuidelOrtho is more favorable than Innovative Eyewear.
Volatility and Risk
QuidelOrtho has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500. Comparatively, Innovative Eyewear has a beta of 2.72, suggesting that its share price is 172% more volatile than the S&P 500.
Summary
QuidelOrtho beats Innovative Eyewear on 7 of the 13 factors compared between the two stocks.
About QuidelOrtho
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
About Innovative Eyewear
Innovative Eyewear, Inc. develops and sells smart eyeglasses and sunglasses. The company's flagship product is Lucyd Lyte glasses that enable the wearer to listen to music, take and make calls, and use voice assistants to perform various smartphone tasks hands-free. It also offers Vyrb, a social media application that enables the user to receive and send posts through Lucyd Lyte smart glasses with voice. In addition, the company launches an application, Lucyd app for iOS/Android users. It sells its products through various e-commerce, and retail store and distribution channels. Innovative Eyewear, Inc. has a license agreement with Lucyd Ltd. The company was incorporated in 2019 and is headquartered in North Miami, Florida. Innovative Eyewear, Inc. is a subsidiary of Lucyd Ltd.
Receive News & Ratings for QuidelOrtho Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for QuidelOrtho and related companies with MarketBeat.com's FREE daily email newsletter.
